1. Home
  2. TYRA vs HURN Comparison

TYRA vs HURN Comparison

Compare TYRA & HURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$25.94

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Huron Consulting Group Inc.

HURN

Huron Consulting Group Inc.

HOLD

Current Price

$110.61

Market Cap

2.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
HURN
Founded
2018
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
TYRA
HURN
Price
$25.94
$110.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
5
Target Price
$47.50
$204.40
AVG Volume (30 Days)
732.5K
225.8K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.34
Revenue
N/A
$1,699,143,000.00
Revenue This Year
N/A
$11.80
Revenue Next Year
N/A
$8.23
P/E Ratio
N/A
$81.83
Revenue Growth
N/A
11.65
52 Week Low
$8.98
$100.10
52 Week High
$40.65
$186.78

Technical Indicators

Market Signals
Indicator
TYRA
HURN
Relative Strength Index (RSI) 26.61 48.13
Support Level $24.88 $100.80
Resistance Level $31.57 $135.59
Average True Range (ATR) 1.84 4.35
MACD -0.68 1.25
Stochastic Oscillator 7.40 87.24

Price Performance

Historical Comparison
TYRA
HURN

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About HURN Huron Consulting Group Inc.

Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.

Share on Social Networks: